ScopeSys
ScopeSys is a Vancouver-based life-science tools company commercializing the patented CLiC tether-free single-molecule imaging platform, selling the ScopeTop benchtop instrument, LNP-specific consumables, and analytical services to genomic-medicine drug developers — particularly mRNA-LNP vaccine and therapy developers — who need single-particle characterization beyond what bulk techniques can provide.
- Company typePrivate
- Founded2021
- HeadquartersMontréal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ScopeSys does
ScopeSys is a Canadian commercial-stage life-science tools company developing single-molecule imaging technology for genomic-medicine drug development. The company serves pharmaceutical and biotechnology researchers developing RNA, DNA, and nanoparticle-delivered therapeutics — most prominently mRNA-LNP vaccine and therapy developers — who need quantitative, single-particle characterization of their formulations. The company's primary application areas are optimizing therapeutic sequences for efficacy and characterizing mRNA loading and LNP structure at single-particle resolution, addressing limitations of bulk techniques such as DLS that cannot resolve particle heterogeneity.
The company's core offering is its patented CLiC (Convex Lens-induced Confinement) platform, a tether-free single-molecule imaging technique that confines molecules in custom nano-geometries and operates under physiological conditions. The platform combines high-throughput single-molecule and single-cell measurements with a state-of-the-art software analysis engine that computes distributions of biophysical properties including kinetic interaction rates, affinities, and conformational states. ScopeSys' first commercial product is the ScopeTop benchtop analytics system, accompanied by an LNP-specific consumable line; these are positioned as drop-in tools that provide quantitative data unbiased for sub-40 nm particles and avoid the surface-tethering artifacts of optical tweezers and SPR.
ScopeSys operates a sales-led, research-collaboration-driven go-to-market model. The company places early-access technology packages in select academic and industry labs as proof-of-concept reference sites, then transitions these into commercial instrument placements and recurring consumable revenue. Revenue is generated across three streams: ScopeTop instrument sales, LNP-specific consumables tied to the installed base, and fee-for-service analytical work performed for genomic researchers worldwide. Distribution is direct, with global reach for analytical services and direct enterprise sales for instruments, supported by content marketing through peer-reviewed publications, webinars (e.g., the March 2026 webinar with Eclipsebio), and academic conference presence.
ScopeSys firmographics
Firmographics- Name
- ScopeSys
- Legal name
- ScopeSys
- Website
- https://scopesys.ca
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ScopeSys is a Vancouver-based life-science tools company commercializing the patented CLiC tether-free single-molecule imaging platform, selling the ScopeTop benchtop instrument, LNP-specific consumables, and analytical services to genomic-medicine drug developers — particularly mRNA-LNP vaccine and therapy developers — who need single-particle characterization beyond what bulk techniques can provide.
- Ownership category
- akta.pro rank
ScopeSys industry classification
Industry- Product category
- Single-Molecule Imaging Instruments
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
Keywords
Where ScopeSys is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
ScopeSys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Instrument Sales: Sale of ScopeTop benchtop analytics system - the company's first commercial benchtop instrument for genetic medicines development.
- Consumables: LNP-specific consumables for use with the CLiC platform, providing recurring revenue from the installed instrument base.
- Analytical Services: Analytical services for genomic researchers worldwide, providing testing and analysis capabilities using the CLiC platform.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
ScopeSys product offering
Product offeringCore offering
ScopeSys develops and commercializes the CLiC (Convex Lens-induced Confinement) single-molecule imaging platform for genomic-medicine drug development. The company sells the ScopeTop benchtop analytics instrument, LNP-specific consumables, and provides analytical services to pharmaceutical, biotechnology, and research customers developing RNA, DNA, and nanoparticle-delivered therapeutics.
Product overview
ScopeSys offers a unified single-molecule analytics platform centered on the CLiC (Convex Lens-induced Confinement) technology, which provides high-throughput measurements with single-molecule and single-cell resolution. The product portfolio includes the ScopeTop benchtop instrument, LNP-specific consumables for mRNA lipid nanoparticle analysis, and associated analytical services. The CLiC platform enables tether-free single-molecule imaging for genomic medicine drug development applications.
Differentiator
Problem solved
Functional benefit
Brands
- ScopeTop™: Benchtop analytics instrument for single-particle analysis in genetic medicines development, including LNP-specific consumables.
Products and services
- CLiC Platform A single-molecule imaging and manipulation platform based on Convex Lens-induced Confinement (CLiC) technology that combines high-throughput measurements with single-molecule and single-cell resolution, operating in physiological conditions without linking chemistry. For pharmaceutical and biotechnology researchers developing RNA, DNA, and nanoparticle-delivered drugs.
- ScopeTop Instrument A benchtop analytics system for genetic medicines development enabling single-particle analytics for mRNA-LNP interactions. Targeted at genomic-medicine drug developers and pharmaceutical researchers.
- LNP-Specific Consumable A consumable product designed specifically for lipid nanoparticle analysis as part of the ScopeTop instrument platform. Provides recurring revenue stream from the installed instrument base for mRNA-LNP characterization workflows.
- Analytical Services Analytical services for genomic researchers worldwide, providing single-molecule analytics for visualizing mRNA lipid nanoparticle interactions using the CLiC platform. Offered to pharmaceutical and biotechnology researchers requiring single-particle characterization without instrument purchase.
Quantifiable outcome
- Single-particle measurements capable of distinguishing and managing outliers vs. DLS which cannot
- +2 more outcomes
Companies that use ScopeSys
Customer profileSegments3 records
Ideal customer profiles2 records
ScopeSys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ScopeSys partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- UBC (University of British Columbia)coreScopeSys is a spin-out company from the Leslie Lab at UBC. The company maintains collaborative relationships with UBC for research and development activities.
- McGill UniversitycoreDr. Sabrina Leslie was a professor in the Physics Department at McGill University from 2012 to 2020. Collaborative research continues with McGill including Albert Kamanzi's PhD work and ongoing sponsored research agreements.
- Harvard UniversitycoreCLiC technology was co-invented at Harvard (Department of Chemistry and Chemical Biology) by Sabrina Leslie and Adam Cohen during her Mary Fieser postdoctoral fellowship from 2009 to 2011.
- FaskenminorLaw firm partner providing legal counsel and services to ScopeSys.
- Vancouver-based Commercial Advisory BoardcoreAdvisory board providing commercial guidance and strategic direction for company growth and market positioning.
- EclipsebiocoreCollaborative partner in March 2026 webinar on advanced imaging and sequencing methods for LNP quality. Dr. Wayne Doyle from Eclipsebio co-presented with ScopeSys CEO on insights into LNP quality enabling RNA drug efficacy improvement.
Scale indicators1 record
Recent moves7 records
Expansion highlights6 records
ScopeSys competitors and assessment
Company assessmentBroad incumbents
- Cytiva (formerly Precision Nanosystems): Cytiva acquired Precision Nanosystems (LNP manufacturing instruments like the NanoAssemblr) in 2021. Provides LNP development/QC instruments to the same mRNA-LNP drug-developer customers ScopeSys targets, making it both a competitor and the most directly relevant acquirer profile.
- Malvern Panalytical: Malvern Panalytical supplies Zetasizer (DLS) and Morphologi (image-based particle characterization) widely used for nanoparticle/LNP size analysis. Broad incumbent serving the same LNP and biopharma QC customers ScopeSys targets, with a much larger installed base and product portfolio.
- Sartorius: Sartorius offers Octet (BLI) bio-layer interferometry instruments and a broader bioprocess portfolio used for molecular interaction analysis and biologics development. Broad incumbent competing for the same analytical-instrument budgets at biopharma customers, with a long-established installed base.
- Wyatt Technology: Wyatt provides multi-angle light scattering (MALS), DLS, and field-flow fractionation instruments for macromolecular and nanoparticle characterization. Broad incumbent in the same analytical-instrument category, competing for the same biopharma characterization budgets.
- Bruker: Bruker's biophysical characterization portfolio includes AFM, mass spectrometry, and microscopy tools used in molecular-interaction and nanoparticle research. Broad incumbent in biophysical/nano characterization with overlap on ScopeSys' core imaging and analytics use cases.
Emerging players
- Refeyn: Refeyn commercializes mass photometry instruments for single-molecule mass measurement in biopharma and academic labs. Comparable emerging player in single-molecule analytics with a benchtop instrument + consumables model serving similar protein and biotherapeutic characterization workflows.
- Eclipsebio: Eclipsebio develops RNA analytics and sequencing-based characterization services for RNA therapeutics, including LNP quality assessment. Explicitly cited as a ScopeSys collaboration partner in March 2026 webinars — overlapping LNP/RNA analytics customer base.
Direct peers
- Lumicks: Lumicks makes single-molecule biophysics instruments (C-Trap optical tweezers, fluorescence microscopy, acoustic force spectroscopy) used to study DNA, proteins, and molecular interactions. Directly comparable to ScopeSys as a single-molecule instrument vendor targeting similar molecular-interaction and drug-development applications.
- NanoTemper Technologies: NanoTemper's Monolith (microscale thermophoresis) and Tycho systems quantify molecular interactions and protein stability without surface immobilization. Directly comparable to CLiC's tether-free, solution-based interaction measurements serving biopharma formulation and biologics development.
- Unchained Labs: Unchained Labs develops benchtop biologics and nucleic-acid characterization instruments (e.g., Uncle for protein stability, Freeslate for formulation). Comparable to ScopeSys as a benchtop life-science analytics company serving biologics/oligonucleotide/formulation developers with recurring consumables.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
ScopeSys social profiles
Digital presenceScopeSys financial estimates
Financial estimateRevenue estimate
Valuation estimate
ScopeSys leadership team
Management profileNumber of profiles
Profiles5 records
ScopeSys funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ScopeSys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ScopeSys
What does ScopeSys do?
ScopeSys develops and commercializes the CLiC (Convex Lens-induced Confinement) single-molecule imaging platform for genomic-medicine drug development. The company sells the ScopeTop benchtop analytics instrument, LNP-specific consumables, and provides analytical services to pharmaceutical, biotechnology, and research customers developing RNA, DNA, and nanoparticle-delivered therapeutics.
Is ScopeSys a public or private company?
ScopeSys is a private company. It is classified as venture growth investor backed and is currently operating.
When was ScopeSys founded?
ScopeSys was founded in 2021. It employs 11 to 50 people.
Where is ScopeSys based?
ScopeSys is headquartered in Montréal, Canada, in the North America region.
How does ScopeSys make money?
Three revenue lines are on record. Instrument Sales are the primary driver. The others are consumables and analytical Services.
Who are ScopeSys's main competitors?
Broad incumbents on record are Cytiva (formerly Precision Nanosystems), Malvern Panalytical, Sartorius, Wyatt Technology and Bruker. Emerging players are Refeyn and Eclipsebio. Direct peers are Lumicks, NanoTemper Technologies and Unchained Labs.
Does ScopeSys have an API?
No public API is recorded for ScopeSys.
What industry is ScopeSys in?
ScopeSys's product category is Single-Molecule Imaging Instruments. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 541714 and its SIC code is 3841.